These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 30553569)

  • 21. Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice.
    Madhun AS; Haaheim LR; Nøstbakken JK; Ebensen T; Chichester J; Yusibov V; Guzman CA; Cox RJ
    Vaccine; 2011 Jul; 29(31):4973-82. PubMed ID: 21600260
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of poly[di(sodium carboxylatophenoxy)phosphazene] (PCPP) as mucosal adjuvant to induce protective immunity against respiratory pathogens.
    Shim DH; Ko HJ; Volker G; Potter AA; Mutwiri G; Babiuk LA; Kweon MN
    Vaccine; 2010 Mar; 28(11):2311-7. PubMed ID: 20060944
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An alphavirus-based adjuvant enhances serum and mucosal antibodies, T cells, and protective immunity to influenza virus in neonatal mice.
    Khalil SM; Tonkin DR; Snead AT; Parks GD; Johnston RE; White LJ
    J Virol; 2014 Aug; 88(16):9182-96. PubMed ID: 24899195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection.
    Ichinohe T; Watanabe I; Ito S; Fujii H; Moriyama M; Tamura S; Takahashi H; Sawa H; Chiba J; Kurata T; Sata T; Hasegawa H
    J Virol; 2005 Mar; 79(5):2910-9. PubMed ID: 15709010
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection.
    Asahi-Ozaki Y; Itamura S; Ichinohe T; Strong P; Tamura S; Takahashi H; Sawa H; Moriyama M; Tashiro M; Sata T; Kurata T; Hasegawa H
    Microbes Infect; 2006 Oct; 8(12-13):2706-14. PubMed ID: 16968669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inactivated Eyedrop Influenza Vaccine Adjuvanted with Poly(I:C) Is Safe and Effective for Inducing Protective Systemic and Mucosal Immunity.
    Kim ED; Han SJ; Byun YH; Yoon SC; Choi KS; Seong BL; Seo KY
    PLoS One; 2015; 10(9):e0137608. PubMed ID: 26355295
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inactivated influenza vaccine adjuvanted with bacterium-like particles induce systemic and mucosal influenza A virus specific T-cell and B-cell responses after nasal administration in a TLR2 dependent fashion.
    Keijzer C; Haijema BJ; Meijerhof T; Voorn P; de Haan A; Leenhouts K; van Roosmalen ML; van Eden W; Broere F
    Vaccine; 2014 May; 32(24):2904-10. PubMed ID: 24598720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The optimized fusion protein HA1-2-FliCΔD2D3 promotes mixed Th1/Th2 immune responses to influenza H7N9 with low induction of systemic proinflammatory cytokines in mice.
    Song L; Xiong D; Kang X; Jiao Y; Zhou X; Wu K; Zhou Y; Jiao X; Pan Z
    Antiviral Res; 2019 Jan; 161():10-19. PubMed ID: 30389471
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity.
    Arulanandam BP; O'Toole M; Metzger DW
    J Infect Dis; 1999 Oct; 180(4):940-9. PubMed ID: 10479116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Respiratory Vaccination with Hemagglutinin Nanoliposomes Protects Mice from Homologous and Heterologous Strains of Influenza Virus.
    Sia ZR; Chiem K; Huang WC; Seffouh A; Teimouri Dereshgi A; Hogan T; Ortega J; Davidson BA; Martinez-Sobrido L; Lovell JF
    J Virol; 2022 Oct; 96(19):e0100622. PubMed ID: 36106872
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. II. Induction of TH1 and TH2 responses in mice.
    Babai I; Samira S; Barenholz Y; Zakay-Rones Z; Kedar E
    Vaccine; 1999 Mar; 17(9-10):1239-50. PubMed ID: 10195637
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit.
    Tamura S; Samegai Y; Kurata H; Nagamine T; Aizawa C; Kurata T
    Vaccine; 1988 Oct; 6(5):409-13. PubMed ID: 2848377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
    Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
    Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.
    Hong SH; Byun YH; Nguyen CT; Kim SY; Seong BL; Park S; Woo GJ; Yoon Y; Koh JT; Fujihashi K; Rhee JH; Lee SE
    Vaccine; 2012 Jan; 30(2):466-74. PubMed ID: 22051136
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunomodulation of TH2 biased immunity with mucosal administration of nanoemulsion adjuvant.
    Bielinska AU; O'Konek JJ; Janczak KW; Baker JR
    Vaccine; 2016 Jul; 34(34):4017-24. PubMed ID: 27317451
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sublingual immunization with a subunit influenza vaccine elicits comparable systemic immune response as intramuscular immunization, but also induces local IgA and TH17 responses.
    Gallorini S; Taccone M; Bonci A; Nardelli F; Casini D; Bonificio A; Kommareddy S; Bertholet S; O'Hagan DT; Baudner BC
    Vaccine; 2014 Apr; 32(20):2382-8. PubMed ID: 24434044
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protective cellular and mucosal immune responses following nasal administration of a whole gamma-irradiated influenza A (subtype H1N1) vaccine adjuvanted with interleukin-28B in a mouse model.
    Sabbaghi A; Zargar M; Zolfaghari MR; Motamedi-Sedeh F; Ghaemi A
    Arch Virol; 2021 Feb; 166(2):545-557. PubMed ID: 33409549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
    Joseph A; Itskovitz-Cooper N; Samira S; Flasterstein O; Eliyahu H; Simberg D; Goldwaser I; Barenholz Y; Kedar E
    Vaccine; 2006 May; 24(18):3990-4006. PubMed ID: 16516356
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant.
    Hasegawa H; Ichinohe T; Strong P; Watanabe I; Ito S; Tamura S; Takahashi H; Sawa H; Chiba J; Kurata T; Sata T
    J Med Virol; 2005 Jan; 75(1):130-6. PubMed ID: 15543590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.